Clinical trials: Liposarcoma, open to volunteers
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated…
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Trial name
- NCT06422806
- Testing
- Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin
- Where
- 268 sites in United States, Canada and 1 more
- Volunteers
- 365 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in…
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma
- Trial name
- NCT05711615
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 16 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Sarcoma
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell…
- Conditions
- Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT06975293
- Testing
- STC-15 in combination with toripalimab, STC-15 monotherapy
- Where
- 14 sites in United States
- Volunteers
- 107 people
- Sponsor
- STORM Therapeutics LTD
Liposarcoma, Prostate Cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
- Conditions
- Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- CDK4i (NCT04557449)
- Testing
- PF-07220060, Letrozole, Fulvestrant
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 430 people
- Sponsor
- Pfizer
Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of…
- Conditions
- Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma
- Trial name
- NCT06498648
- Testing
- Abemaciclib, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Soft Tissue Sarcoma (STS)
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')
- Conditions
- Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
- Trial name
- 'SARATOGA' (NCT07741877)
- Testing
- Lifileucel
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Retroperitoneal Sarcoma, Liposarcoma
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS…
- Conditions
- Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
- Trial name
- STRASS2 (NCT04031677)
- Testing
- Surgery, Preoperative chemotherapy
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 250 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Neuroblastoma, Ewing Sarcoma
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors.
- Conditions
- Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma
- Trial name
- NCT06541262
- Testing
- Silmitasertib, Irinotecan, Temozolomide
- Where
- 24 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Milton S. Hershey Medical Center
Tumor Hyperinsulinism (Tumor HI)
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
- Trial name
- Tumor HI (NCT06881992)
- Testing
- Ersodetug
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 16 people
- Sponsor
- Rezolute
Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma
Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
This phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and myxoid/round cell liposarcoma that has spread from…
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma, Unresectable Myxoid Liposarcoma, Unresectable Synovial Sarcoma
- Trial name
- NCT07686367
- Testing
- Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Retroperitoneal Sarcoma, Liposarcoma
A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
This phase I trial tests the safety, side effects, and best dose of abemaciclib and how well it works with radiation therapy before surgery in treating patients with high-risk adipocytic retroperitoneal sarcoma.
- Conditions
- Retroperitoneal Sarcoma, Liposarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT06025747
- Testing
- Abemaciclib, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma.
- Conditions
- Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma
- Trial name
- NCT06843967
- Testing
- Mirdametinib, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Resectable Liposarcoma, Resectable Soft Tissue Sarcoma
Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall
This phase III trial compares the effect of adding doxorubicin and ifosfamide (AIM chemotherapy) before (neoadjuvant) receiving standard treatment with pembrolizumab, radiation therapy and surgery to standard of care treatment…
- Conditions
- Resectable Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT07823491
- Testing
- Biospecimen Collection, Computed Tomography, Doxorubicin
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)
Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma
The primary objective of this randomized phase II trial is to assess, independently in advanced/metastatic UPS and DDLPS, the antitumor activity of DT-7012 combined with doxorubicin as first-line systemic therapy.
- Trial name
- IMMUSARC-7012 (NCT07802652)
- Testing
- DT-7012, Doxorubicin
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Solid Tumor
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors.
- Trial name
- NCT06578624
- Testing
- SA53-OS (phase 1), SA53-OS (phase 2)
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Lamassu Bio Inc
Solid Tumors, Sarcoma
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
- Trial name
- NCT06644755
- Testing
- DS-2243a
- Where
- 7 sites in United States, Belgium and 3 more
- Volunteers
- 150 people
- Sponsor
- Daiichi Sankyo
Dedifferentiated Liposarcoma
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options. Immunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in…
- Trial name
- PERELI (NCT06389799)
- Testing
- Pemigatinib, Retifanlimab
- Where
- 4 sites in Norway, Sweden
- Volunteers
- 33 people
- Sponsor
- Lund University Hospital
Myxoid Liposarcoma, Round Cell Liposarcoma
N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
This early phase I trial tests the safety and how well N-803 works in treating patients with synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) that is growing, spreading, or getting worse (progressive) after being…
- Conditions
- Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
- Trial name
- NCT07261657
- Testing
- Biospecimen Collection, Computed Tomography, Leukapheresis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Seth Pollack
Liver Cancer, Rhabdomyosarcoma
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment.
- Conditions
- Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma
- Trial name
- NCT04715191
- Testing
- CARE T cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Baylor College of Medicine
Adipocytic Neoplasm, Liposarcoma
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin…
- Conditions
- Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma
- Trial name
- NCT06239272
- Testing
- Surgical resection, Proton beam radiation therapy, Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- St. Jude Children's Research Hospital